XORTX Therapeutics (XORTX Therapeutics) Gross-Profit-to-Asset %

: 0.00% (As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. XORTX Therapeutics's annualized Gross Profit for the quarter that ended in Sep. 2023 was $0.00 Mil. XORTX Therapeutics's average Total Assets over the quarter that ended in Sep. 2023 was $7.22 Mil. Therefore, XORTX Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 was 0.00%.

XORTX Therapeutics Gross-Profit-to-Asset % Historical Data

The historical data trend for XORTX Therapeutics's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XORTX Therapeutics Annual Data

Trend

Feb15

Feb16

Feb17

Dec18

Dec19

Dec20

Dec21

Dec22

Gross-Profit-to-Asset %

XORTX Therapeutics Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
Gross-Profit-to-Asset %																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, XORTX Therapeutics's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

XORTX Therapeutics Gross-Profit-to-Asset % Distribution

For the Biotechnology industry and Healthcare sector, XORTX Therapeutics's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where XORTX Therapeutics's Gross-Profit-to-Asset % falls into.

XORTX Therapeutics Gross-Profit-to-Asset % Calculation

XORTX Therapeutics's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2022 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2022 )	/	( (Total Assets (A: Dec. 2021 )	+	Total Assets (A: Dec. 2022 ))	/ count )
	=	0	/	( (17.283	+	12.344)	/ 2 )
	=	0	/	14.8135
	=	0.00 %

XORTX Therapeutics's annualized Gross-Profit-to-Asset % for the quarter that ended in Sep. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Sep. 2023 )	/	( (Total Assets (Q: Jun. 2023 )	+	Total Assets (Q: Sep. 2023 ))	/ count )
	=	0	/	( (7.801	+	6.64)	/ 2 )
	=	0	/	7.2205
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Sep. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

XORTX Therapeutics Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of XORTX Therapeutics's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

XORTX Therapeutics (XORTX Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XORTX Therapeutics Inc (NAS:XRTX) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

ANUA:Germany XRTX:Canada

Address

3710 - 33rd Street NW, Calgary, AB, CAN, T2L 2M1

Website

https://www.xortx.com

XORTX Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and potentially commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism and uric acid metabolism in orphan (rare) disease indications such as ADPKD and T2DN, as well as AKI associated with respiratory virus infection. Its focus is on developing three therapeutic products to slow or reverse the progression of chronic kidney disease, address the immediate need of individuals facing AKI associated with respiratory virus infection and identify other opportunities where existing and new intellectual property can be leveraged to address health issues.